Published studies also report that defects in ATM or ATR signaling can be synthetically lethal with PARP inhibition [26], and although pre-clinical evidence for the use of PARP inhibitors in MM exists, a biomarker-based approach has not been evaluated clinically [27,28]. Here, ATM is linked to Miyoshi myopathy.